Pfizer presents, publishes follow-up results from PHAROS trial of BRAFTOVI + MEKTOVI ($24.51, 0.00)
Ono presents two-year efficacy and safety results from MOTION study of ROMVIMZA (¥1812.5000, 0)
LegoChem Biosciences receives milestone payment for LCB97 from Ono pharmaceutical; terms undisclosed
Powered by FactSet Research Systems Inc.